Accueil・Liste d'Actions・Ovid therapeutics Inc

Ovid therapeutics Inc

Fermé

SecteurSoins de santé

2.91 3.56

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

2.65

Max

2.84

Chiffres clés
By Trading Economics
Revenu	2M -15M
Ventes	733K 733K
BPA	-0.08
Marge bénéficiaire	-2,047.476
Employés	23
EBITDA	566K -16M

Recommandations
By TipRanks
Recommandations	Achat Fort
Prévisions sur 12 Mois	+121.63% upside

Dividendes
By Acuity
Prochains Résultats	11 nov. 2026

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	50M 539M
Ouverture précédente	-0.65
Clôture précédente	2.91

Sentiment de l'Actualité

By Acuity

50%

150 / 340 Classement par Healthcare

Ovid therapeutics Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

24 août 2026, 19:16 UTC

Ovid Therapeutics Inc shares are higher today, recovering from an earlier dip. The stock remains above its 20-day moving average and last month's price.

21 août 2026, 19:46 UTC

Ovid Therapeutics Inc is trading higher, maintaining a position near its one-month range. Shares pulled back earlier in the session but are advancing overall.

20 août 2026, 23:31 UTC

Ovid Therapeutics Inc shares are higher in after-market trading, reflecting a significant shift in momentum since Thursday's close. No specific news was identified.

19 août 2026, 21:21 UTC

Ovid Therapeutics shares declined in after-market trading, finishing near the day's low after peaking earlier in the session. The stock remains above its 20-day moving average.

14 août 2026, 19:53 UTC

Social Media

Ovid Therapeutics Inc shares are higher as the company advances its clinical pipeline, with key data releases planned through 2026, attracting positive market sentiment.

13 août 2026, 19:16 UTC

Social Media

News

Ovid Therapeutics reported Q2 EPS of -$0.08, surpassing estimates. Shares are trading higher as the company advances its clinical pipeline and maintains $169.8 million in cash.

12 août 2026, 19:46 UTC

Ovid Therapeutics Inc shares are higher, supported by positive sentiment from a recent inflation report, despite earlier declines in the session.

7 août 2026, 19:26 UTC

Ovid Therapeutics Inc shares are lower today amid broader market dynamics. The stock briefly peaked earlier in the session before declining.

6 août 2026, 22:51 UTC

Ovid Therapeutics Inc. shares are lower in after-market trading, declining since Thursday's close despite remaining above its 20-day moving average.

5 août 2026, 21:03 UTC

Ovid Therapeutics Inc shares are higher in after-market hours, continuing a positive trend from four consecutive days of gains. No specific news was identified.

4 août 2026, 23:01 UTC

Ovid Therapeutics Inc shares are lower in after-market trading, with no specific news identified to explain the decline since Tuesday's close.

3 août 2026, 19:11 UTC

News

Ovid Therapeutics shares are higher as Oppenheimer raises the price target to $9.00 from $7.00, maintaining an Outperform rating.

31 juil. 2026, 20:02 UTC

Ovid Therapeutics Inc shares are lower today amid rising Treasury yields and crude oil prices, contributing to broader inflation concerns affecting the biotechnology sector.

27 juil. 2026, 20:07 UTC

Ovid Therapeutics Inc shares are higher during Monday's session, following a cumulative gain since Friday. The stock pulled back from earlier session highs.

22 juil. 2026, 18:46 UTC

Ovid Therapeutics Inc shares are lower amid broader market volatility linked to rising crude oil prices and geopolitical tensions, with no specific news identified.

20 juil. 2026, 19:36 UTC

Ovid Therapeutics Inc shares are lower today, continuing a trend of declines amid broader market pressure from geopolitical tensions and rising oil prices.

Comparaison

Variation de prix

Ovid therapeutics Inc prévision

Objectif de Prix

By TipRanks

121.63% hausse

Prévisions sur 12 Mois

Moyen 6.25 USD 121.63%

Haut 9 USD

Bas 4 USD

Basé sur 6 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

6 ratings

Achat

Maintien

Vente

Basé sur 6 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Sentiment

By Acuity

150 / 340Classement par Soins de santé

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Ovid therapeutics Inc

Ovid Therapeutics Inc., a biopharmaceutical company, engages in the development of impactful medicines for patients and families with epilepsies and seizure-related neurological disorders in the United States. The company is developing soticlestat, a novel cholesterol 24 hydroxylase inhibitor, which is in Phase 3 clinical trials for the potential treatment of patients with resistant epilepsies; OV329, a GABA aminotransferase inhibitor which is in Phase 1 clinical trials for the treatment of seizures associated with tuberous sclerosis complex and infantile spasms; and OV350, a small molecule direct activator of the KCC2 transporter, which is in Phase 1 clinical trials for treating epilepsies. It also develops OV815, that focuses on the mutations associated with KIF1A-associated neurological disorder (KAND); OV888 (GV101), a highly selective rock2 inhibitor which is in Phase 1 double-blind multiple-ascending dose trial; OV825, has advanced to potential candidate lead identification for the rare neurodevelopmental condition HNRNPH2 (Bain Syndrome); and OV882, a short hairpin RNA gene therapy for the treatment of Angelman syndrome. The company has license and collaboration agreements with Healx, AstraZeneca AB, H. Lundbeck A/S, Northwestern University, and Graviton, as well as Marinus Pharmaceuticals, Inc. The company was incorporated in 2014 and is headquartered in New York, New York.